The intended audience for this activity is endocrinologists, urologists, primary care physicians, cardiologists, and specialists interested in the management and treatment of hypogonadism
Despite evidence to the contrary, persistent concerns about the relationship between testosterone and the prostate continue to impede the treatment of hypogonadism. Mounting evidence demonstrates that there is a lack of association between testosterone therapy and prostate cancer progression, and preliminary studies have investigated the role of testosterone therapy in patient populations for whom it was once not considered. At present, there are strong indications that eugonadal testosterone levels play a protective role in the natural history of prostate cancer. Furthermore, preliminary studies suggest that testosterone therapy may improve lower urinary tract symptoms (LUTS). Because hypogonadism and LUTS are associated, it is critical to optimize the management of these comorbid conditions. Various studies support the proven benefits of testosterone therapy, which include increased lean body mass, decreased fat mass, and improved bone mineral density, sexual desire, and function. To overcome barriers to successful treatment of hypogonadism, physicians need targeted education focused on properly diagnosing hypogonadism, safely initiating testosterone therapy, and monitoring patients receiving testosterone therapy.
At the conclusion of this activity, participants should be better able to...
- Evaluate new evidence related to the relationship between testosterone therapy, prostate cancer, and benign prostatic hyperplasia (BPH)
- Review the role that testosterone therapy may have in the management of lower urinary tract symptoms in hypogonadal men with BPH
- Optimally manage hypogonadism, ED and BPH/LUTS to improve treatment outcomes)
ACCREDITATION AND CERTIFICATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Dannemiller and Cognimed. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians. Dannemiller designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has no fee and should take approximately 1 hour to complete. Participants should first read the objectives and introductory CE information, then proceed to the educational offering. To receive credit for this activity participants must complete the post-test with a passing score of 80%, then complete the evaluation. This credit is valid through February 28, 2015. No credit will be given after this date. Statements of Credit will be provided by web-certification or mail following activity participation and upon completion and return of the evaluation form to CogniMed Inc via submission at the end of the activity; by mail to CogniMed Inc, 70 South Orange Avenue, Suite 230, Livingston, NJ 07039; or by fax to 973-758-0052. Please allow 4 to 6 weeks for the delivery of your statement. If you have any questions about your certificate, please e-mail email@example.com.
CONTENT REVIEW STATEMENT
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.
It is the policy of Dannemiller to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed. The faculty for this activity have disclosed that there will be discussion about the use of products for non—FDA-approved indications. In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Dannemiller policy, the following disclosures have been made:
Mark T. Nadeau, MD, MBA, FAAFP, Clinical Content Reviewer, has nothing to disclose.
Gordon Ringler, Project Manager, has nothing to disclose.
CogniMed Inc. Staff
Estelle Perera, Senior Director, Scientific Affairs and Program Design, has nothing to disclose.
Nancy Vogel, Production Editor, has nothing to disclose.
Culley C. Carson III, MD, discloses he is an investigator for Auxilium Pharmaceuticals, Inc, is a speaker for Auxilium Pharmaceuticals, Inc, and a consultant to Auxilium Pharmaceuticals, Inc, Coloplast, and AMS.
Martin M. Miner, MD, discloses he is an investigator for Forest Laboratories, and a consultant to Endo Pharmaceuticals.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of CogniMed Inc or Dannemiller, by Lilly USA, LLC, and Abbvie. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive on the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely on the information contained within this educational activity.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of Dannemiller and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. Dannemiller disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Sponsored by Dannemiller.
This activity is supported by educational grant provided by Lilly USA, LLC, and Abbvie.
© 2014 CogniMed Inc. All rights reserved. TU15146 February 2014